Skip to main content
Clinical Trials/NCT02235389
NCT02235389
Terminated
Not Applicable

A Multicentre, Feasibility Study of Pre-hospital Treatment of Acute Myocardial Infarction Based on Diagnosis by Interpretation of Remotely Acquired ECG and Thrombolysis With Accelerated Alteplase ( Actilyse®). Pre-Hospital Alteplase Remote Advice of Hospital (PHARAOH)

Boehringer Ingelheim0 sites59 target enrollmentFebruary 1998

Overview

Phase
Not Applicable
Intervention
Alteplase (Actilyse)
Conditions
Myocardial Infarction
Sponsor
Boehringer Ingelheim
Enrollment
59
Primary Endpoint
Percentage of equipment function / reliability
Status
Terminated
Last Updated
11 years ago

Overview

Brief Summary

The general aim of this study was to assess the feasibility of treating acute myocardial infarction (AMI) by physician-directed pre-hospital thrombosis, using accelerated alteplase (Actilyse®) and a diagnostic technique involving remote electrocardiogram (ECG) acquisition by paramedics

Registry
clinicaltrials.gov
Start Date
February 1998
End Date
December 1998
Last Updated
11 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Ischemic cardiac pain of \>= 20 minutes and \<= 6 hours
  • Age 18 - 80 years
  • Ability to give informed consent (witnessed verbal or written)
  • Ability to follow protocol and comply with follow -up requirements

Exclusion Criteria

  • Current participation in another clinical trial
  • Patient will be ineligible for pre hospital administration of actilyse if any of the following apply:
  • Acute myocardial infarction (AMI) treated with a thrombolytic agent within the preceding 4 days
  • BP (blood pressure) \> 180/100 mmHg (on one measurement)
  • Significant bleeding disorder within the past 6 months
  • Major surgery, biopsy of a parenchymal organ, or significant trauma (including any trauma associated with the current AMI) within 3 months
  • History of stroke, transient ischaemic attack, or central nervous system structural damage (e.g. neoplasm, aneurysm, intracranial surgery)
  • Oral anticoagulation
  • Recent (within 10 days) non - compressible vascular puncture
  • Pregnancy (positive urine pregnancy test) or lactation, parturition within the previous 30 days, or female of childbearing potential not using adequate birth control (oral contraception)

Arms & Interventions

Administration of thrombolytic treatment with PHARAOH

Pre-Hospital Alteplase Remote Advice of Hospital (PHARAOH)

Intervention: Alteplase (Actilyse)

Standard therapy with thrombolytic treatment in Hospital

Intervention: Standard therapy

Outcomes

Primary Outcomes

Percentage of equipment function / reliability

Time Frame: Up to 12 month after drug administration

Time between pre-hospital evaluation and treatment

Time Frame: Up to 12 month after drug administration

Percentage of acute myocardial infarction (AMI) patients, whose symptoms were recognized by paramedics

Time Frame: Up to 12 month after drug administration

Percentage of patients correctly diagnosed as suffering acute myocardial infarction by remote ECG interpretation

Time Frame: Up to 12 month after drug administration

Percentage of patients incorrectly diagnosed as suffering acute myocardial infarction by remote ECG interpretation

Time Frame: Up to 12 month after drug administration

Percentage of patients receiving pre- hospital thrombolysis in the absence of a subsequently confirmed diagnosis of acute myocardial infarction

Time Frame: Up to 12 month after drug administration

Percentage of patients giving consent to pre- hospital evaluation using remote electrocardiogram (ECG)

Time Frame: Up to 12 month after drug administration

Number of patients with adverse events

Time Frame: Up to 12 month after drug administration

Patient status at 30 days post myocardial infarction

Time Frame: Up to 30 days after drug administration

Similar Trials